TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29241520
Drug: Dementia-specific training
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dementia-specific training program for nurses using a mobile phone applet, details on dosage and duration not specified.
Study: 23052610
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza A/H1N1 vaccine
Study: 19968580
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg dutasteride
Study: 19968580
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg dutasteride
Study: 19968580
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dutasteride daily for 2‐4 weeks
Study: 19968580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication for patients)
Study: 15383199
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus Lovastatin 20 mg
Study: 15383199
Drug: Lovastatin administration
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin administration alone
Study: 11530717
Drug: Respiratory biofeedback
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory biofeedback therapy using a handheld capnometry device for 4 weeks
Study: 9624543
Drug: Ceftibuten (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (400 mg od for 5 days)
Study: 9624543
Drug: Amoxycillin/clavulanate (250/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (250/125 mg tds for 10 days)
Study: 7936843
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 300 U/kg three times a week s.c. and iron at 6 mg/kg/d
Study: 7936843
Drug: Iron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron at 3 mg/kg/d (control group)
Study: 29198057
Drug: Individual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual physical therapy alone
Study: 29198057
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (individual physical therapy alone)
Study: 23633679
Drug: Selenium 200
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 µg/d for 3 months
Study: 23576623
Drug: cabergoline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: cabergoline (3 mg/day)
Study: 23576623
Drug: levodopa (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa (300 mg/day)
Study: 11731181
Drug: Gelestra (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelestra (17 beta-estradiol gel 0.6 mg/g)
Study: 11731181
Drug: Estraderm TTS
Normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estraderm TTS 50 (transdermal delivery system)
Study: 7996377
Drug: Itraconazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (5 and then 10 mg/kg per day)
Study: 7996377
Drug: Historical group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical group (daily ketoconazole prophylaxis)
Study: 3209324
Drug: RePUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RePUVA therapy (PUVA started with retinoids, gradually increased to 4 j/cm2 by the beginning of the third week)
Study: 20102633
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified breakfast cereal (16 mg iron per serve) with two ZESPRI(R) GOLD kiwifruit
Study: 20102633
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified breakfast cereal (16 mg iron per serve) with a banana (low ascorbic acid and carotenoid content)
Study: 18257146
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day DRI
Study: 18257146
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day DRI
Study: 11515638
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education programme administered by schoolteachers
Study: 2899102
Drug: Cetirizine 2
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 2 HCl, 10 mg once a day
Study: 30234740
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (initiated after day 7)
Study: 30234740
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (initiated within 24 hours)
Study: 19934445
Drug: Face‐to‐face training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face‐to‐face training sessions using music therapy
Study: 16136768
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg once daily for 4 weeks
Study: 9917116
Drug: Lovastatin 10
Normalized name: lovastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 10 mg/d, titrated to 20 mg/d and 40 mg/d at 8 and 16 weeks, respectively.
Study: 7743786
Drug: Imipramine drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine drug therapy (Drug)
Study: 7743786
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy (IPT‐M)
Study: 7743786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPT‐M and Drug
Study: 2344059
Drug: 1% rectal
Normalized name: Proctofoam 1% Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% rectal methohexital (25 mg/kg)
Study: 2344059
Drug: 10% rectal
Normalized name: Cortifoam 10% Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% rectal methohexital (25 mg/kg)
Study: 24131528
Drug: Automated, interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, interactive cognitive behaviour training (CB training), completed weekly with email reminders.
Study: 17596903
Drug: Drug court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug court intervention (outpatient treatment with drug court supervision)
Study: 17596903
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment without drug court supervision
Study: 16878198
Drug: No sealing
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sealing (same treatment as Group II)
Study: 14526927
Drug: Uranium gastrointestinal
Normalized name: uranium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uranium gastrointestinal absorption (f1) values
Study: 10871912
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (HRT) and bisphosphonate
Study: 10871912
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy with testosterone
Study: 10871912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alendronate and parathyroid hormone (PTH)
Study: 10871912
Drug: Tiludronate and
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate and PTH, calcitonin and PTH, calcitonin and anabolic steroids
Study: 1474172
Drug: DI‐Antalvic (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DI‐Antalvic (30 mg dextropropoxyphene and 400 mg paracetamol per capsule, 6 capsules/day for 1 week)
Study: 1474172
Drug: Efferalgan‐Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efferalgan‐Codeine (30 mg codeine and 500 mg paracetamol per tablet, 6 tablets/day for 1 week)
Study: 6725915
Drug: Immunoreactive measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoreactive measurement of trypsin excretion
Study: 29231298
Drug: Four-hand-needling therapy
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-hand-needling therapy (Sanjian (LI 3), Wailaogong (EX‐UE 8), Zhongzhu (TE 3), Houxi (SI 3) on the affected side)
Study: 29231298
Drug: Routine needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine needling therapy at neck‐Jiaji (EX‐B 2) on bilateral C4, C5 and C6
Study: 24096683
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg
Study: 24096683
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (CLcr >90 mL/min)
Study: 19020154
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac 10 mg
Study: 12798613
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Study: 12798613
Drug: Intradermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Study: 11355929
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all‐trans retinoic acid (ATRA) and conventional anthracycline‐ARA‐C chemotherapy (CT)
Study: 11355929
Drug: Prolonged maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged maintenance treatment with ATRA and low dose CT
Study: 11355929
Drug: Rapid onset
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid onset of CT and/or high dose steroids for ATRA syndrome
Study: 28538556
Drug: Juvéderm Voluma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvéderm Voluma (2 ml injected)
Study: 24231251
Drug: Relative telomere
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative telomere length (RTL) measured by quantitative PCR on blood or buccal cell DNA
Study: 21989182
Drug: Adjuvant fluorouracil/folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant fluorouracil/folinic acid (FU/FA) treatment
Study: 11777094
Drug: Sequential mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential mixed frequency stimulation from a standard device
Study: 8495604
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg EPA-E
Study: 8495604
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg EPA-E
Study: 8495604
Drug: Placebo (1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1656 mg olive oil)
Study: 30388160
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg DNA-IIV3
Study: 24317366
Drug: E+R (epigallocatechin-gallate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+R (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1))
Study: 24317366
Drug: E+R+S (epigallocatechin-gallate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+R+S (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1) + soy isoflavones 80 mg day(‐1))
Study: 22992814
Drug: Anterior route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior route of injection
Study: 22992814
Drug: Lateral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral route of injection
Study: 22992814
Drug: Posterior route
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior route of injection
Study: 22992814
Drug: Posterior route
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior route of injection in females
Study: 22992814
Drug: Posterior route
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior route of injection in males
Study: 20560909
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 1000 μg
Study: 20560909
Drug: Fluticasone proprionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone proprionate (FP) 1000 μg
Study: 18633020
Drug: Intraoperative IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative IV dexamethasone 8 mg and ondansetron 4 mg, followed by 8 mg oral disintegrating ondansetron tablet on discharge and in the morning of postoperative days 1 and 2.
Study: 18633020
Drug: Intraoperative IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative IV ondansetron 4 mg (control group).
Study: 15863529
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (300 mug/d)
Study: 2405109
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 75 mg/m2 and doxorubicin (Dox) 50 mg/m2 intravenously every 3 weeks
Study: 2405109
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) and doxorubicin (Dox) as neoadjuvant therapy
Study: 2405109
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) and doxorubicin (Dox) as sole therapy
Study: 2405109
Drug: Multimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality therapy (CT followed by surgery or radiation therapy)
Study: 7437258
Drug: Prolintane (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolintane (15 mg)
Study: 7437258
Drug: Prolintane (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolintane (30 mg)
Study: 7437258
Drug: Pemoline (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (60 mg)
Study: 7437258
Drug: Pemoline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (100 mg)
Study: 30388242
Drug: Supplemental protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental protein feeding (four commercially available protein supplements, wildflower pollen supplement)
Study: 25281275
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control strategy (including electrical cardioversion and pharmacotherapy)
Study: 20571180
Drug: Eszopiclone co-administered
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone co-administered with fluoxetine (ESZ+FLX)
Study: 20571180
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with fluoxetine (PBO+FLX)
Study: 15763646
Drug: Soy capsules
Normalized name: Nature's Way Estrosoy Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy capsules
Study: 2678162
Drug: VALERINA NATT
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VALERINA NATT (valerian preparation)
Study: 31849040
Drug: Inspiratory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory oxygen fraction of 0.80 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Study: 31849040
Drug: Inspiratory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory oxygen fraction of 0.30 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Study: 24635002
Drug: Short-term Psychoanalytic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term Psychoanalytic Child Therapy (PaCT), 20-25 sessions
Study: 24635002
Drug: Short-term Psychoanalytic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term Psychoanalytic Child Therapy (PaCT)
Study: 18083471
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lornoxicam infusion 30 minutes before skin incision
Study: 18083471
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion immediately after skin closure (control group)
Study: 16128938
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg once daily
Study: 14585672
Drug: New TBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: New TBE vaccine
Study: 14585672
Drug: Formerly licensed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formerly licensed TBE vaccine
Study: 9076651
Drug: Methadone formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone formulation change
Study: 6205336
Drug: salm-calcitonin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: salm-calcitonin and polychemo-therapy or hormonal treatment
Study: 6205336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcitonin therapy)
Study: 30694881
Drug: Milk thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk thistle (150 mg to 300 mg twice a day)
Study: 28343976
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (25 Gy in ten daily fractions of 2·5 Gy)
Study: 26536022
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine (1-6 mg per dose, mean 3.4 mg) administered 3 times at 2-hour intervals
Study: 21233014
Drug: TPF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF (docetaxel 75 mg/m², cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 4 days)
Study: 21233014
Drug: PF (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF (cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 5 days)
Study: 15389416
Drug: Low-energy-dense salad
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-dense salad (0.33 kcal/g) small portion (150 g)
Study: 15389416
Drug: Low-energy-dense salad
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-dense salad (0.33 kcal/g) large portion (300 g)
Study: 15389416
Drug: High-energy-dense salad
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-dense salad (1.33 kcal/g) small portion (150 g)
Study: 15389416
Drug: High-energy-dense salad
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-dense salad (1.33 kcal/g) large portion (300 g)
Study: 12090907
Drug: Fosinopril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril monotherapy (20 mg daily for 30 months)
Study: 12090907
Drug: Hydrochlorothiazide and
Normalized name: hydrochlorothiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and hydralazine combination
Study: 9520174
Drug: COL‐1492 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL‐1492 gel
Study: 8061724
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (11.1 mumol/kg/min) + Amino acids infusion (3.33 mg/kg/min for last 4 hours)
Study: 8061724
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (Lipovenös, 10% 10 ml/min for 7.5 h) + Amino acids infusion (for last 4 hours)
Study: 8061724
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (10% 10 ml/min) + Amino acids infusion (for last 4 hours)
Study: 959765
Drug: Exogenous hormones
Normalized name: Exogenous hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous hormones (secretin and CCK)
Study: 28719287
Drug: DPIV formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPIV formulations (1 or 4 μg with aluminum hydroxide or 1 μg with AS01E or AS03B)
Study: 28719287
Drug: DPIV formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPIV formulations
Study: 26553086
Drug: Zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (10 mg/PO/bed time)
Study: 24119468
Drug: FIR-radiated therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR-radiated therapy (40-minute radiation at the major lesion site or anastomosed site three times a week)
Study: 24119468
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (free-radiated usual therapy)
Study: 24119468
Drug: FIR-radiated therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR-radiated therapy
Study: 17526179
Drug: Acupoint drug-finger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint drug-finger pressing (ADFP) on Ganshu (BL18), Danshu (BL19), Weishu (BL21), and Pishu (BL20) acupoints, 15 min each time, twice per day for 3 weeks.
Study: 17526179
Drug: Acid-inhibitory and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-inhibitory and gastrokinetic drugs (omeprazole 20 mg once every 12 hours and cisapride 10 mg thrice daily before meals) for 3 weeks.
Study: 9663911
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure monitoring for 2 weeks (6 work days, duplicate measurements, twice daily)
Study: 31876052
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Echinacea angustifolia root extract twice daily for 7 days
Study: 31876052
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily for 7 days
Study: 31389880
Drug: Surgical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical antibiotic prophylaxis before hand surgery